Back to Search
Start Over
Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis
- Source :
- Business Wire India (Delhi-NCR, India). June 6, 2019
- Publication Year :
- 2019
-
Abstract
- Cambridge, June 6 -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) today announced that the Phase 3 TOURMALINE-AL1 clinical trial in patients with relapsed or refractory systemic light-chain (AL) amyloidosis [...]
- Subjects :
- Takeda Pharmaceutical Company Ltd. -- Product development
Clinical trials
Ixazomib
Amyloidosis
Lithium compounds -- Product development
Medical care quality
Pharmaceutical industry -- Product development
Dexamethasone -- Product development
Physicians
Recurrence (Disease)
Glucocorticoids
Business, international
Ninlaro (Medication)
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Business Wire India (Delhi-NCR, India)
- Publication Type :
- News
- Accession number :
- edsgcl.587961545